Semaglutide

Estimated Market Price

$169.99 – $184.99

Based on verified supplier pricing for research-grade compounds

GLP-1 receptor agonist for weight management and metabolic health. Pharmaceutical-grade, third-party verified purity.

How it works

Mimics GLP-1, a natural hormone that tells your brain you're full and signals your body to burn stored fat for energy. A fatty acid tail keeps it active in your system for about a week.

Performance

Weight Management

bestseller

What to Expect

Week 1–4 Appetite reduction begins; mild GI adjustment expected. Noticeably less hungry; portions feel too big. Some nausea early on.

Week 5–8 Noticeable weight loss of 3–5%; dose titration continues. Clothes fitting looser; cravings for junk food fading.

Week 9–12 Metabolic markers improving; steady weight loss trend. Visible weight loss; people start commenting. Energy up.

Week 13–16 Significant body composition change; reassess target dose. Body looks different in the mirror; confidence growing.

Week 17+ Maintenance phase; sustained appetite control and weight loss. New baseline - smaller appetite feels normal now.

Verified Suppliers

For research purposes only. These suppliers have been independently verified by PepSpace. We do not process sales directly.

PepSpace is not affiliated with any listed supplier

LarnaLabs Verified Supplier · larnalabs.com

PepSpace Verified Supplier · pepspace.io

BioSynth Verified Custom Batch Supplier · biosynth.com

Peptide Sciences Unavailable · peptidesciences.com

Protocol & Dosage

Typical Dosage 0.25 mg/week titrating to 1–2.4 mg/week SC

Administration Subcutaneous injection, Oral

Schedule Once weekly, same day each week

Protocol Duration 12–16+ weeks (ongoing for weight management)

Half-Life ~7 days (once-weekly dosing)

Side Effects & Safety

Tolerability Profile Moderate

Notable side effects likely; manageable with proper awareness

Common Side Effects

Nausea~44%
Diarrhea~30%
Vomiting~24%
Constipation~24%
Abdominal pain~20%
Headache~14%
Fatigue~11%
Dyspepsia~9%
Dizziness~7%
Bloating~7%

Less Common

Gallstones or cholecystitis1–3%
Hair loss~3%
Increased heart rate (+1-4 bpm)1–3%
Injection site reaction~1%
Flatulence~1%
GERD / acid reflux~1%

Rare / Serious

Pancreatitis<0.3%
Acute kidney injury (from dehydration)rare
Gastroparesis (delayed gastric emptying)rare

Discontinue If

Severe abdominal pain radiating to back (pancreatitis)
Persistent vomiting or inability to eat or drink
Neck lump, hoarseness, or difficulty swallowing (thyroid)
Jaundice or dark urine (gallbladder/liver)
Signs of severe allergic reaction

Contraindications

Personal or family history of medullary thyroid carcinoma
Multiple endocrine neoplasia type 2 (MEN2)
History of pancreatitis
Pregnancy or breastfeeding
Severe gastroparesis

Data note: Extensively studied in STEP/SUSTAIN trials (10,000+ participants). GI side effects are dose-dependent and typically diminish over 4-8 weeks.

Always consult a qualified healthcare professional before use. This information is for research reference only and does not constitute medical advice.

Ask about Semaglutide

How to Apply

Gather

Peptide vial, BAC water, alcohol swabs, insulin syringe

Sanitize

Wipe tops of both vials with alcohol swabs

Draw

Pull 1–2 mL of BAC water into syringe

Add Water

Release water slowly along vial wall, not directly on powder

Swirl

Roll between palms until dissolved. Never shake.

Store

Refrigerate 2–8°C, use within 30 days

Frequently Asked Questions

Yes. Bacteriostatic water (BAC water) is required to reconstitute lyophilized (freeze-dried) peptides. It contains 0.9% benzyl alcohol which prevents bacterial growth, keeping your reconstituted peptide safe for multiple uses over up to 30 days.

Unreconstituted: store at -20°C (freezer) for long-term, or 2–8°C (fridge) for short-term. After reconstitution: always refrigerate at 2–8°C and use within 30 days. Keep away from direct sunlight.

Results vary by individual and protocol. In research settings, measurable effects are typically observed within 1–4 weeks depending on the specific peptide, dosage, and application. Consult a qualified professional for guidance.

Verified suppliers typically include a full third-party COA verifying purity (99%+), identity, and sterility. We recommend only sourcing from vendors that provide batch-specific testing data.

We list verified suppliers above that have been independently reviewed for product quality, testing transparency, and shipping reliability. Always verify COA data before sourcing.

Compound Profile

Scientific data & classification for Semaglutide

Also Known As Ozempic, Wegovy, Rybelsus

Classification GLP-1 Receptor Agonist · Metabolic

Sequence Modified GLP-1(7-37) - His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(C18 fatty diacid)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly (31 aa)

Molecular Formula C₁₈₇H₂₉₁N₄₅O₅₉

Molecular Weight 4,113.58 Da

CAS Number 910463-68-2

Half-Life ~7 days (once-weekly dosing)

Origin Synthetic analog of human GLP-1

Administration Subcutaneous injection, Oral

Status FDA Approved - diabetes (2017), weight management (2021)

Mechanism of Action Mimics GLP-1, a natural hormone that tells your brain you're full and signals your body to burn stored fat for energy. A fatty acid tail keeps it active in your system for about a week.

Research Overview Semaglutide represents one of the most significant pharmacological advances of the 21st century, having fundamentally altered the treatment landscape for both type 2 diabetes and obesity. Developed by Novo Nordisk and first approved by the FDA in December 2017 for type 2 diabetes (as Ozempic), semaglutide is a long-acting glucagon-like peptide-1 receptor agonist engineered with a C18 fatty di-acid acylation at lysine-26 and an amino acid substitution at position 8 (Aib for Ala) that collectively provide strong non-covalent albumin binding and resistance to DPP-4 enzymatic degradation. These modifications extend the pharmacokinetic half-life from the native GLP-1 peptide's approximately 2 minutes to roughly 7 days, enabling once-weekly subcutaneous dosing. The SUSTAIN clinical trial program established semaglutide's superiority over other GLP-1 receptor agonists and most existing diabetes therapies in both glycemic control and weight reduction. The subsequent STEP trial program demonstrated that higher-dose semaglutide (2.4 mg weekly) produced mean weight loss of approximately 15-17% of body weight in individuals with obesity - results unprecedented for any pharmacological intervention and approaching the efficacy of bariatric surgery. The landmark SELECT cardiovascular outcomes trial further demonstrated a 20% reduction in major adverse cardiovascular events independent of diabetes status. An oral formulation (Rybelsus) achieved regulatory approval in 2019, utilizing a proprietary absorption enhancer (SNAC) to enable gastrointestinal uptake of the peptide. The molecular pharmacology of semaglutide involves activation of GLP-1 receptors in pancreatic beta cells to enhance glucose-dependent insulin secretion, in alpha cells to suppress glucagon, in gastric smooth muscle to delay emptying, and in hypothalamic appetite-regulating centers - particularly the arcuate nucleus and the nucleus tractus solitarius - to reduce hunger and increase satiety signaling.

Citations

Published findings on Semaglutide from peer-reviewed journals.